Clinical Characteristics of Long-Term Survivors After Sorafenib Treatment for Unresectable Hepatocellular Carcinoma: A Korean National Multicenter Retrospective Cohort Study by 김도영 et al.
O R I G I N A L  R E S E A R C H
Clinical Characteristics of Long-Term Survivors 
After Sorafenib Treatment for Unresectable 
Hepatocellular Carcinoma: A Korean National 
Multicenter Retrospective Cohort Study
Young Youn Cho,1,2 Su Jong Yu,1 
Hye Won Lee,3 Do Young Kim,3 
Wonseok Kang,4 Yong-Han Paik, 4 
Pil Soo Sung,5 Si Hyun Bae,6 
Su Cheol Park,7 Young Seok Doh,8,9 
Kang Mo Kim, 9 Eun Sun Jang,10 
In Hee Kim,11 Won Kim,12 
Yoon Jun Kim 1
1Department of Internal Medicine and Liver 
Research Institute, Seoul National University 
College of Medicine, Seoul, Korea; 2Department of 
Internal Medicine, Chung-Ang University Hospital, 
Seoul, Korea; 3Department of Internal Medicine, 
Yonsei University College of Medicine, Seoul, 
Korea; 4Department of Medicine, Samsung Medical 
Center, Sungkyunkwan University School of 
Medicine, Seoul, Korea; 5Department of Internal 
Medicine, Seoul St. Mary’s Hospital, The Catholic 
University of Korea College of Medicine, Seoul, 
Korea; 6Department of Internal Medicine, 
Eunpyeong St. Mary’s Hospital, The Catholic 
University of Korea College of Medicine, Seoul, 
Korea; 7Department of Internal Medicine, Korea 
Cancer Center Hospital, Korea Institute of 
Radiological and Medical Sciences, Seoul, Korea; 
8Department of Internal Medicine, Eulji University 
Hospital, Daejeon, Korea; 9Department of 
Gastroenterology, Asan Liver Center, Asan Medical 
Center, University of Ulsan College of Medicine, 
Seoul, Korea; 10Departments of Internal Medicine, 
Seoul National University Bundang Hospital, Seoul 
National University College of Medicine, Seoul, 
Korea; 11Department of Internal Medicine, 
Chonbuk National University Hospital, Chonbuk 
National University Medical School, Cheongju-si, 
Korea; 12Department of Internal Medicine, Seoul 
Metropolitan Government Seoul National 
University Boramae Medical Center, Seoul, Korea 
Background/Aim: Sorafenib is the first systemic therapy for the treatment of advanced- 
stage hepatocellular carcinoma (HCC) and progressive HCC after locoregional therapy. 
The aim of this study was to evaluate the prognostic factors of long-term survivors after 
sorafenib treatment.
Methods: This multicenter, retrospective, cohort study included 1,566 unresectable HCC 
patients who received sorafenib treatment between 2007 and 2014 in nine tertiary centers in 
Korea. The patients were classified into a long-term survivor group (survival more than two 
years, n = 257) or a control group (n = 1309). The primary outcomes were the prognostic 
factors affecting long-term survival. Secondary endpoints included time-to-progression and 
other safety profiles.
Results: The patients were predominantly men (83.8%) with chronic hepatitis B (77.3%) 
and Barcelona clinic of liver cancer-stage C (BCLC-C) (78.3%). The median overall survival 
was 9.0 months. After treatment, eight patients (0.4%) achieved complete response and 139 
patients (8.8%) achieved partial response according to the mRECIST criteria. The prognostic 
factors predicting long-term survival were metformin use (adjusted hazard ratio [aHR] = 
3.464; P < 0.001), hand-foot skin reaction (aHR = 1.688; P = 0.003), and concomitant 
treatment with chemoembolization or radiotherapy (aHR = 2.766; P < 0.001). Poor prog-
nostic factors of long-term survival were a Child-Pugh score of B (HR = 0.422; P < 0.001), 
the presence of extrahepatic metastasis (HR = 0.639; P = 0.005), main portal vein invasion 
(HR = 0.502; P = 0.001), and elevated alpha-fetoprotein (>1,000 ng/mL; HR = 0.361; P < 
0.001).
Conclusion: This large, multicenter, retrospective study showed an objective response rate 
of 9.1% and a proportion of long-term survivors of 16.4% in Korean patients. The prognostic 
factors derived in our study can be used in clinical practice during sorafenib treatment.
Keywords: sorafenib, hepatocellular carcinoma, prognosis, survival
Introduction
Hepatocellular carcinoma (HCC) is the leading cause of death worldwide, and the 
burden of HCC is likely to increase in the future.1,2 Hepatitis B is the most common 
cause of liver disease and HCC in Korea.3 Although chronic liver disease patients 
are under a strict surveillance program, less than 30% of newly diagnosed HCC 
patients are detected in the curative stage.4 The five-year survival rate of 
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unresectable HCC has improved recently, but the prog-
nosis of unresectable HCC is still poor.
Sorafenib is a multi-tyrosine kinase inhibitor that 
impedes cell proliferation and angiogenesis. Sorafenib 
was approved for use in Korea based on two large-scale 
randomized controlled studies: the Sorafenib 
Hepatocellular Carcinoma Assessment Randomized 
Protocol (SHARP) trial and the Asia-Pacific (AP) trial.5,6 
Sorafenib is currently the standard systemic therapy 
approved to treat HCC in patients with well-preserved 
liver function (Child-Pugh class A), advanced-stage HCC 
(BCLC-C), and progressive HCC after locoregional ther-
apy. Recently, atezolizumab plus bevacizumab has demon-
strated better overall survival compared to sorafenib.7 
Novel treatment options for HCC have been developed, 
including lenvatinib for first-line treatment and regorafe-
nib, nivolumab, cabozantinib, and ramucirumab 
for second-line treatment.8 However, sorafenib is still 
important in advanced HCC treatment because current 
first-line options other than atezolizumab plus bevacizu-
mab are not superior to sorafenib, and most second-line 
treatments occur in a clinical setting where sorafenib treat-
ment has failed.
Several previous studies have examined the prognostic 
factors that favor sorafenib treatment. A previous Japanese 
study descriptively analyzed profiles of patients who have 
survived for more than three years after sorafenib treat-
ment that included conversion surgery following success-
ful sorafenib treatment, additional salvage options in 
progressive disease, long-term sorafenib treatment, and 
good pre-treatment liver functions.9 Another nationwide 
survey in Japan examined the clinical characteristics of 
patients who obtained a complete response (CR) after 
sorafenib administration found that the prognostic factors 
in the CR group included female sex, low body weight 
(<59 kg), early clinical stage, and a small initial dose of 
sorafenib, implying that it was difficult to predict respon-
ders using patients’ baseline clinical characteristics.10 
Several studies focused on the on-treatment values of 
biomarkers such as alpha-fetoprotein (AFP), which predict 
sorafenib response.11,12 Moreover, previous studies have 
demonstrated that the development of adverse events, such 
as skin toxicity, diarrhea, and hypertension, was associated 
with improved survival after sorafenib treatment.13,14
Given the multiple treatment options for unresectable 
HCC, clinicians need to identify patients who will benefit 
from sorafenib treatment. However, little data are available 
regarding the clinical characteristics of good responders. 




From January 2007 to March 2014, 1,566 consecutive 
patients who underwent sorafenib treatment and met our 
inclusion/exclusion criteria were included in this study. 
The study protocol conformed to the ethical guidelines of 
the World Medical Association Declaration of Helsinki 
and was approved by the Institutional Review Board of 
Seoul National University Hospital and all the other cen-
ters. Informed consent was waived in Seoul National 
University and all the other centers since the research 
involves no more than minimal risk to the subject, the 
waiver will not adversely affect the rights and welfare of 
the subjects, and the research could not practicably be 
done without a waiver of consent. Non-identified informa-
tion was used in order to protect the patients’ 
confidentiality.
The inclusion criteria were as follows: (a) clinical or 
histological diagnosis of HCC based on the American 
Association for the Study of Liver Diseases 
guidelines;15,16 (b) unresectable HCC with BCLC stage 
B or C; (c) tumor conditions confirmed by abdominal 
imaging (contrast-enhanced computed tomography [CT] 
and/or magnetic resonance imaging [MRI]) performed 
within two months before sorafenib administration; (d) 
treatment response evaluated by abdominal imaging (con-
trast-enhanced CT and/or MRI) at least once after sorafe-
nib treatment; and (e) patients with a Child-Pugh Score of 
A or B. The exclusion criteria were as follows: (a) 
a previous history of receiving other systemic therapies 
(except for hepatic arterial infusion of chemotherapy, 
molecularly targeted agents, or immunotherapy for HCC 
treatment before sorafenib treatment); (b) concomitant ser-
ious medical conditions requiring medicine whose packa-
ging recommends caution when co-administering; and (c) 
previous or concurrent cancer that has a primary site or 
histology distinct from HCC, except for cervical carci-
noma in situ, treated basal cell carcinoma, superficial 
bladder tumors [Ta, Tis, and T1], or any cancer curatively 
treated less than three years prior enrolment.
Sorafenib Treatment
Patients received a starting dose of sorafenib of 400 mg 
twice daily. In case of adverse events, sorafenib doses 
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were adjusted according to each treating physician. 
Treatment was continued until tumor progression or intol-
erable toxicity.
Endpoints and Assessment
The index date of this study was set as the initial date of 
sorafenib treatment. We defined long-term survivors as 
patients surviving more than two years and short-term 
survivors as those surviving less than two years after 
sorafenib treatment. This period was decided based on 
the consensus of the multicenter study participants and 
previous studies.
The primary outcome of this study was the clinical 
characteristics of long-term survivors after sorafenib treat-
ment. The secondary study objectives were (a) prognostic 
survival factors for all patients; (b) overall survival (OS, 
months) in all patients; and (c) safety profiles, especially 
off-target effects (skin toxicity, diarrhea, and arterial 
hypertension) in all patients.
Tumor response was assessed in each patient by the 
treating physician. Tumor response and disease progres-
sion were evaluated using the modified Response 
Evaluation Criteria in Solid Tumors (mRECIST) criteria, 
which assess treatment response by measuring the longest 
diameters of all arterial enhancing lesions. HCC showing 
no arterial enhancement was defined as complete respon-
ders (CR), and cases in which the viable portion was 
reduced by at least 30% were defined as partial responses 
(PR). Cases in which the viable portion increased by at 
least 20% or with newly developed lesions were defined as 
progressive disease (PD), and the remaining cases were 
defined as stable disease (SD). Safety profiles were eval-
uated according to the overall incidence of each adverse 
event based on the medical records. The presence or 
absence of off-target effects, including skin toxicities, 
diarrhea, and arterial hypertension, was recorded. 
Adverse events were graded according to Common 
Terminology Criteria for Adverse Events, version 4.03.
Statistical Analysis
To compare baseline characteristics, we used a two-sample 
t-test or the Kruskal–Wallis test for continuous variables 
and the Fisher exact test or the Chi-square test for non-
continuous variables. The Kaplan–Meier method was used 
to estimate survival and the Log rank test was used to 
compare survival curves. Univariate analysis was per-
formed by the Cox proportional hazards model or the 
logistic regression model, and prognostic factors found to 
be significant in the univariate analysis were then com-
bined in a multivariate Cox proportional hazards model or 
in a multivariate logistic regression model to obtain the 
optimal prediction model.
Cumulative OS and time to progression after sorafenib 
administration was calculated by the Kaplan–Meier 
method. The determination of the antitumor effect was 
based on objective tumor assessments documented by 
each physician in the medical record according to 
mRECIST. Additionally, the response assessment was re- 
evaluated by an on-site radiologist according to mRECIST 
principles to accurately determine sorafenib effectiveness.
Univariable and multivariable Cox proportional 
hazards models were used to identify OS risk factors and 
to evaluate clinical variables in a specific subgroup, such 
as long-term survivors. Multivariable analysis variables 
were determined based on their statistical significance in 
the univariable analysis. To avoid multicollinearity, the 
forward conditional stepwise procedure was performed in 
the multivariable analysis. OS according to significant risk 
factors was compared using the Log rank test. All statis-
tical analysis was performed using SPSS software (SPSS 
version 20.0; SPSS, Chicago, Ill). A two-sided P value of 
< 0.05 was considered statistically significant.
Results
A total of 1,566 patients were included in this study; 257 
in the long-term survivor group and 1,309 patients in the 
short-term survivor group. The patients were predomi-
nantly men (83.8%) with chronic hepatitis B (77.3%) and 
BCLC stage C (78.3%). The long-term survivor group had 
favorable baseline characteristics. A significantly higher 
proportion of the long-term survivors had a Child-Pugh 
score of A (89.9% vs 75.3%, P < 0.001; Table 1) and 
BCLC stage B (34.1% vs 18.0%, P < 0.001) than the 
short-term survivor group. In addition, a significantly 
lower proportion of the long-term survivor group had 
Vp3–4 portal vein tumor thrombosis (PVTT, 15.5% vs 
31.4%, P < 0.001), and AFP > 1,000 ng/mL (17.5% vs 
39.0%, P < 0.001). The long-term survivor group had 
a shorter tumor diameter (3.64 cm vs 5.26 cm, P< 0.001) 
and fewer HCC nodules (2.71 vs 3.89, P < 0.001) than the 
short-term survivor group.
The median OS was 9.0 months (Figure 1A), and the 
median time to progression (TTP) was 3.0 months 
(Figure 1B). After treatment, eight patients (0.4%) 
achieved CR and 147 patients (8.8%) achieved PR accord-
ing to the mRECIST criteria (Table 2).
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Table 1 Baseline Characteristics
Long Term Survivor (N=257) Short Term Survivor (N=1,309) P value*
Age 58.66 ± 10.12 57.94 ± 10.65 0.163
Sex
Male 213 (82.6) 1099 (84.0) 0.580
Diabetes 40 (15.5) 148 (11.3) 0.074
BMI 0.007
< 23 121 (47.1) 727 (56.6)
23–25 60 (23.3) 282 (22.0)
> 25 76 (29.6) 275 (21.4)
Etiology 0.514
Hepatitis B 196 (76.0) 1045 (80.3)
Hepatitis C 23 (8.9) 84 (6.5)
Alcoholic liver disease 14 (5.4) 70 (5.4)
Non alcoholic fatty liver disease 9 (3.5) 39 (3.0)
Others 16 (6.2) 64 (4.9)
ECOG performance 0.003
0 132 (55.5) 577 (46.9)
1 102 (42.9) 572 (46.5)
2–4 4 (1.7) 80 (6.5)
Maximum diameter (cm) 3.64 ± 3.96 5.26 ± 4.58 <0.001
Number of HCC nodules 2.71 ± 3.19 3.89 ± 3.68 <0.001
Child Pugh score <0.001
A 232 (89.9) 986 (75.3)
B 26 (10.1) 323 (24.7)
BCLC Stage <0.001
B 88 (34.1) 236 (18.0)
C 170 (65.9) 1073 (82.0)
Extrahepatic metastasis 127 (49.2) 543 (41.5) 0.023
Lymph node 40 (15.5) 365 (27.9) <0.001
Lung 100 (38.8) 573 (43.8) 0.149
Bone 20 (7.8) 130 (9.9) 0.300
Brain 0 (0) 9 (0.7) 0.182
Adrenal 9 (3.5) 55 (4.2) 0.731
Peritoneal-seeding 15 (5.8) 7.6 (99) 0.361
PVTT <0.001
Vp1–2 13 (5.0) 127 (9.7)
Vp3 17 (6.6) 188 (14.4)
Vp4 23 (8.9) 223 (17.0)
AFP (ng/mL) <0.001
<7 81 (31.5) 221 (17.0)
7–1000 131 (51.0) 572 (44.0)
1000–10,000 31 (12.1) 265 (20.4)
>10,000 14 (5.4) 242 (18.6)
Notes: Values are presented as mean±standard deviation or number (%) unless otherwise indicated; *Quantitative variables by 2-sample t-test, qualitative variables by chi- 
square test. 
Abbreviations: BMI, body mass index; ECOG, Eastern Cooperative Oncology Group; BCLC, Barcelona Clinic Liver Cancer; PVTT, portal vein tumor thrombosis; Vp1, 
segmental portal vein invasion; Vp2, right anterior/posterior portal vein; Vp3, right/ left portal vein; Vp4, main trunk; AFP, alpha-fetoprotein.
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Long-Term Survivors
The long-term survivor group included more patients trea-
ted with a lower dose of sorafenib (mean 634 mg vs 
662 mg, P=0.032, Table 2) than the short-term survivor 
group, although the difference was minimal. Sorafenib 
duration was significantly longer in the long-term survivor 
group (median 8.6 months vs 3.0 months, P < 0.001) than 
in the short-term survivor group. Only the long-term sur-
vivor group included patients who achieved CR. 
Moreover, the long-term survivor group had a higher pro-
portion of PR (14.7% vs 7.7%) and SD (62.0% vs 35.3%) 
than the short-term survivor group. In addition, SD dura-
tion was significantly longer in the long-term survivor 
group (46.7 months vs 14.5 months) than in the short- 
term survivor group. There was a higher proportion of 
patients with a decrease in AFP of more than 20% at the 
first evaluation in the long-term survivor group (41.4% vs 
25.1%) than in the short-term survivor group.
Eight patients achieved CR after sorafenib treatment 
(Supplemental Table 1). Some patients had a favorable 
tumor burden. Three (37.5%) patients had Vp3–4 PVTT, 
two (25.0%) had extrahepatic metastasis, and three 
(37.5%) received concomitant trans-arterial chemoemboli-
zation (TACE) treatment. We compared the clinical 
characteristics of the patients achieving PR and the num-
ber of HCC (2.70 vs 3.83, respectively; Supplemental 
Table 2) and the proportion of AFP > 1,000 ng/mL 
(43.6% vs 23.2, respectively) was different. Patients with 
Child Pugh B showed unfavorable baseline characteristics 
compared to patients with Child Pugh A (Supplemental 
Table 3). And patients with initial AFP > 1,000 ng/mL 
showed unfavorable baseline characteristics compared to 
patients with initial AFP ≤ 1,000 ng/mL (Supplemental 
Table 4). There were more concomitant treatment, and less 
extrahepatic metastasis in patients with decrease in AFP of 
more than 20% at the first evaluation compared to patients 
with AFP decrease less than 20% or AFP increase at the 
first evaluation (Supplemental Table 5).
In the multivariable analysis, the prognostic factors 
predicting long-term survival include metformin use 
(adjusted hazard ratio [aHR] = 3.464; 95% confidence 
interval [CI], 1.875–6.402; P < 0.001; Table 3), dermato-
logical adverse reactions (aHR = 1.688; 95% CI, 1.196– 
2.384; P = 0.003; Table 3), a high body mass index (aHR = 
1.577; 95% CI, 1.102–2.258; P = 0.043; Table 3), and 
concomitant treatment with chemoembolization or radio-
therapy (aHR = 2.766; 95% CI, 2.016–4.213; P < 0.001; 
Table 3). Poor prognostic factors for long-term survival 
were a high Child-Pugh score (aHR = 0.422; 95% CI, 
Figure 1 The median overall survival was 9.0 months (A) and the median time to progression was 3.0 months (B), respectively. Modified Response Evaluation Criteria in 
Solid Tumors criteria estimated the response.
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0.264–0.674; P < 0.001; Table 3), the presence of extra-
hepatic metastasis (HR = 0.639; 95% CI, 0.469–0.871; P = 
0.005; Table 3), main portal vein invasion (aHR= 0.502; 
95% CI, 0.296–0.853; P = 0.001), and AFP levels >1,000 
ng/mL (aHR = 0.361; 95% CI, 0.224–0.583; P < 0.001; 
Table 3).
The clinical characteristics of patients treated conco-
mitantly with chemoembolization or radiotherapy were 
comparable to those of patients treated with sorafenib 
monotherapy (Supplemental Table 6). The number of 
HCC nodules was smaller in the concomitant treatment 
group than in the group without concomitant treatment 
(2.45 vs 3.83, P = 0.017).
Survival
The median OS was 9.0 months (Figure 1A), and the 
median time to progression was 3.0 months. Patients 
with overall adverse event grades of 2–4 or 0–1 had 
comparable survival; however, patients with dermatolo-
gic adverse event grades of 2–4 had better median survi-
val than patients with dermatologic adverse event grades 
of 0–1 (median 10.7 months vs 8.5 months, respectively, 
P = 0.002 by Log rank test). Patients who underwent 
concomitant treatment had better median survival rates 
than those without concomitant treatment (median 13.2 
months vs 8.3 months, respectively, P < 0.001 by Log 
rank test). Patients who received salvage treatment after 
sorafenib treatment failure had better median survival 
than those who did not receive salvage treatment (median 
13.5 months vs 6.7 months, respectively, P < 0.001 by 
Log rank test).
In the multivariable analysis, the prognostic factors pre-
dicting OS and long-term survival were comparable 
(Supplemental Table 7). The only difference was that the 
body mass index was not a prognostic factor in predicting OS.
Safety
Overall adverse events over grade 2 were similar between 
the long-term survivor and the short-term survivor groups 
(41.9% vs 37.7%, respectively, P = 0.205; Table 4). 
However, there were more adverse events over grade 3 
(7.8% vs 12.7%, respectively, P = 0.025) and fewer 
Table 2 Clinical Characteristics of Long-Term Survivors Compared to Short-Term Survivors
Long-Term Survivor (N=257) Short-Term Survivor (N=1,309) P value*
Sorafenib dose (mg) 634 662 0.032
Treatment duration of sorafenib (median, mo) 8.6 3.0 <0.001
Best overall response <0.001
CR 8 (3.5) 0 (0)
PR 38 (14.7) 101 (7.7)
SD 160 (62.0) 462 (35.3)
PD 51 (19.8) 746 (57.0)
SD duration (month) 11.18 ± 11.71 4.17 ± 3.23 <0.001
PR duration (month) 9.53 ± 14.55 3.39 ± 2.88 0.014
CR duration (month) 13.63 ± 15.91
Ratio of AFP at first evaluation <0.001
< 80% 103 (41.4) 292 (25.1)
80–120% 64 (25.7) 248 (21.3)
> 120% 82 (32.9) 622 (53.5)
Concomittent treatment 71 (27.5) 158 (12.1) <0.001
Salvage treatment 150 (58.1) 420 (32.1) <0.001
Sorafenib as first line treatment 65 (25.2) 407 (31.1) 0.059
Notes: Values are presented as mean±standard deviation or number (%) unless otherwise indicated; *Quantitative variables by 2-sample t-test, qualitative variables by chi- 
square test. 
Abbreviations: CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; AFP, alpha-fetoprotein.
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dermatologic adverse events (28.3% vs 17.9%, respec-
tively, P < 0.001) in the short-term survivor group than 
in the long-term survivor group.
Discussion
This is a large retrospective cohort study of 1,566 HCC 
patients who underwent sorafenib treatment in a hepatitis 
B endemic area. The median OS was 9.0 months. After 
treatment, 9.1% of patients achieved an objective response 
according to mRECIST criteria. The prognostic factors 
favoring long-term survival were metformin use, dermato-
logic adverse reactions, and concomitant treatment with 
chemoembolization or radiotherapy. Poor prognostic fac-
tors of long-term survival were a high Child-Pugh score, 
Table 3 Prognostic Factors for Long-Term Survivors (Survival > 2 Years) After Sorafenib Treatment
Variable Univariate HR (95% CI) P value Multivariate HR (95% CI) P value*
Age 1.006 (0.994–1.019) 0.319
Sex
Female 1.106 (0.776–1.575) 0.578
BMI 0.007 0.043
<23 1 1
23–25 1.278 (0.911–1.794) 1.125 (0.765–1.654)
25–30 1.660 (1.207–2.284) 1.577 (1.102–2.258)
ECOG 0.006 0.027
0 1 1
1 0.779 (0.587–1.035) 0.766 (0.563–1.044)
2–4 0.219 (0.079–0.607) 0.286 (0.099–0.828)
Child Pugh score <0.001 <0.001
A 1 1
B 0.342 (0.224–0.523) 0.422 (0.264–0.674)
Extrahepatic metastasis 0.731 (0.559–0.956) 0.022 0.639 (0.469–0.871) 0.005
PVTT <0.001 0.001
None 1 1
Vp1–2 0.385 (0.213–0.695) 0.483 (0.254–0.920)
Vp3 0.340 (0.202–0.572) 0.396 (0.223–0.700)
Vp4 0.388 (0.246–0.612) 0.502 (0.296–0.853)
AFP (ng/mL) <0.001 <0.001
<7 1 1
7–1,000 0.514 (0.379–0.698) 0.568 (0.404–0.799)
1,000–10,000 0.315 (0.206–0.482) 0.361 (0.224–0.583)
> 10,000 0.156 (0.087–0.277) 0.211 (0.112–0.397)
Diabetes 1.438 (0.985–2.099) 0.060
Metformin Use 3.202 (1.856–5.526) <0.001 3.464 (1.875–6.402) <0.001
Statin Use 1.136 (0.650–1.987) 0.655
Adverse event Gr 2–4 versus. Gr 0–1 1.192 (0.908–1.563) 0.205
Dermatologic adverse event Gr 2–4 versus. Gr 0–1 1.813 (1.335–2.461) <0.001 1.688 (1.196–2.384) 0.003
Gastroenterologic adverse event Gr 2–4 versus. Gr 0–1 1.378 (0.910–2.085) 0.130
Concomittent treatment 2.766 (2.009–3.808) <0.001 2.915 (2.016–4.213) <0.001
Note: *By logistic regression. 
Abbreviations: BMI, body mass index; ECOG, Eastern Cooperative Oncology Group; PVTT, portal vein tumor thrombosis; AFP, alpha-fetoprotein; Gr, grade.
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the presence of extrahepatic metastasis, main portal vein 
invasion, and elevated AFP levels.
Important data regarding prognosis after sorafenib 
treatment comes from the SHARP and AP studies.17 
A recent subgroup analysis of these studies showed that 
the presence of macroscopic vascular invasion, high AFP 
levels, and a high neutrophil-to-lymphocyte ratio were 
prognostic factors in sorafenib treatment.17 Several studies 
suggested that dermatologic adverse events, diarrhea, 
Child-Pugh score, BCLC stage, sorafenib dose, etiology, 
metformin treatment, and extrahepatic spread may be 
prognostic factors.18 In our study, well-known prognostic 
factors such as the Child-Pugh score, the extent of PVTT, 
high AFP levels, and poor performance were prognostic 
factors for long-term survival. Previous research indicates 
that extrahepatic metastasis is an important prognostic 
factor in sorafenib treatment,19 and our study supports 
that this is an independent negative prognostic factor of 
long-term survival.
There have been several biomarker studies on sorafe-
nib treatment. Our work validates that the AFP response 
during sorafenib treatment can predict prognosis.11 In pre-
vious research, early AFP increase four weeks after sor-
afenib treatment predicted progressive disease and poor 
survival.12 The fact that the AFP response rate was sig-
nificantly higher in the long-term survivor group than in 
the short-term survivor group can be applied in clinical 
practice. Previous biomarker studies have also evaluated 
blood inflammatory markers, such as changes in the neu-
trophil-to-lymphocyte ratio, to predict prognosis.17,20,21 
There also have been several molecular biomarkers stu-
dies. High ACSL4 expression, a positive-activating 
enzyme of ferroptosis, could predict a good response to 
sorafenib.22 A recent study showed that stratification using 
VEGFR2, PDGFRB, c-KIT, c-RAF, EGFR, mTOR, and 
FGFR1 gene expression could predict sorafenib 
response.23 However, these studies could not be evaluated 
due to the retrospective nature of our study and a lack of 
laboratory data.
We found that concomitant treatment with TACE or RT 
predicts long-term survival and OS. The Global 
Investigation of therapeutic DEcisions in hepatocellular 
carcinoma and Of its treatment with sorafeNib 
(GIDEON) study24 demonstrated the safety of combining 
TACE with sorafenib, and several retrospective studies 
have shown the efficacy of combined TACE and sorafenib 
treatments in survival benefit and tumor response.25–27 
However, recent clinical trials comparing the efficacy of 
sorafenib plus TACE with TACE alone in intermediate 
HCC28 and a Phase 3 trial comparing the same in 
advanced HCC29 indicate that the combination treatment 
did not improve OS. Although a recent Phase 3 clinical 
trial has shown that TACE in combination with sorafenib 
has no survival that benefits patients, subgroup analysis 
has evaluated that receiving more than two TACE sessions 
showed better OS in the combination group.29 External 
beam radiotherapy and brachytherapy using Y-90 are 
widely used to treat unresectable HCC.30 A recent 
Korean randomized control study showed that TACE com-
bined with radiotherapy resulted in better OS than sorafe-
nib in HCC with portal vein invasion.31 And a recent 
Japanese randomized trial has shown that TACE plus 
sorafenib significantly improved PFS over TACE, imply-
ing the potential of the combination treatment.32 Our study 
showed that concomitant locoregional treatment is 
a positive prognostic factor for long-term survival. 
Table 4 Safety Profiles After Sorafenib Treatment
Long-Term Survivor (N=257) Short-Term Survivor (N=1,309) P value*
AE all grades (%) 176 (68.2) 846 (64.6) 0.269
AE grade 2–4 (%) 108 (41.9) 493 (37.7) 0.205
AE grade 3–4 (%) 20 (7.8) 166 (12.7) 0.025
Dermatologic adverse event grade 2–4 (%) 73 (28.3) 234 (17.9) <0.001
Gastroenterologic adverse event grade 2–4 (%) 32 (12.4) 122 (9.3) 0.128
Hypertension grade 2–4 (%) 0 2 (0.2) 0.530
Note: *By chi-square test. 
Abbreviation: AE, adverse events.
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Further studies might elucidate a certain subgroup favor-
ing the combination treatment which we could not specify.
Research suggests that metformin use can reduce resis-
tance to sorafenib and improve OS.33,34 Metformin is asso-
ciated with improved survival in other treatments for 
HCC.35,36 Metformin can also reduce HCC development, 
and recurrence after curative treatments.37,38 Our study 
showed that metformin use was associated with long-term 
survival even after adjusting for diabetes. These findings 
cannot justify the routine use of metformin, but we can 
include metformin in order of priority when treating cases 
of HCC with pre-existing diabetes. A recent meta-analysis 
showed that dermatologic adverse events are a beneficial 
indicator for HCC patients receiving sorafenib, and several 
reports suggest that hypertension and gastrointestinal 
adverse events are as well.39 However, the results of our 
study indicate that only dermatologic adverse events were 
associated with long-term survival after sorafenib treatment.
A strength of our study is that it is a large, multicenter 
cohort study that provides information in a setting where 
hepatitis B is the predominant cause of liver cirrhosis. The 
efficacy of sorafenib was significantly different between 
etiologies, and hepatitis B was a poor prognostic factor.40 
It is important to study the efficacy of sorafenib in differ-
ent etiologies. Our study is the largest retrospective study 
evaluating the outcomes of sorafenib treatment in an HBV 
endemic area. A limitation of our study is its retrospective 
nature, although this design allows us to determine the 
appropriate associations. Ongoing or future clinical trials 
with a sufficient number of patients are warranted.
In conclusion, this large multicenter retrospective study 
of Korean patients demonstrated an objective response of 
9.1% and a proportion of long-term survivors of 16.4%. 
The prognostic factors derived in our study can be used in 
clinical practice during sorafenib treatment.
Highlights
This multicenter, retrospective, cohort study included 
1,566 unresectable HCC Korean patients who received 
sorafenib treatment. The objective response rate was 
9.1%, and the proportion of long-term survivors was 
16.4%. The prognostic factors predicting long-term survi-
val were metformin use, hand-foot skin reaction, and con-
comitant treatment with chemoembolization or 
radiotherapy. Poor prognostic factors of long-term survival 
were a Child-Pugh score of B, the presence of extrahepatic 
metastasis, main portal vein invasion, and elevated alpha- 
fetoprotein levels.
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